Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60

Benzinga · 1d ago
Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.